EN CN


Target Based Assays

Return

Poly (ADP-ribose) polymerases (PARPs)

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes involved in DNA repair, genomic stability, and programmed cell death. PARP enzymes detect and respond to DNA damage by adding ADP-ribose polymers to target proteins, facilitating the recruitment of repair proteins to sites of damage. Dysregulated PARP activity is implicated in multiple diseases, particularly cancer, where PARP inhibitors have emerged as a therapeutic strategy, especially in tumors with defective DNA-repair mechanisms such as BRCA1/2-mutated cancers.

PARP Assay Services

PARP Enzymatic Assays

We use an ELISA-based method to detect the enzymatic activity of PARP family members. Histones are coated on the plate, and PARP proteins, together with biotin-labeled NAD, are added to the reaction. PARP1, PARP2, and PARP3 require single-strand DNA breaks for activation. As the reaction proceeds, PARP1 forms biotin-labeled ADP-ribose chains on histones. Streptavidin-labeled HRP and an ultrasensitive detection reagent are then used to generate the assay signal.

PARP Trapping Assay

When PARP forms a complex with DNA and NAD, it normally dissociates from DNA as ADP-ribose chains are generated. In this assay, biotin labels are introduced at single-stranded DNA breaks and PARP proteins are tagged with His tags. Inhibitor-induced PARP–DNA retention can then be detected through a fluorescence resonance energy transfer signal between donor and acceptor tags.

PARP Binding Assay

PARP1 and PARP2 binding can be evaluated using Fluorescence Polarization (FP) and Surface Plasmon Resonance (SPR). FP supports rapid, high-throughput assessment of small-molecule binding affinity, while SPR provides real-time kinetic analysis of association and dissociation. Together, these methods support comprehensive profiling of PARP binding properties.

PARP Target and Assay Coverage
TargetSynonymsAssay TypeReference CompoundAssay Format
PARP1ADPRT, PPOLActivityOlaparib, AZD5305Luminescence
PARP1ADPRT, PPOLBindingOlaparib, AZD5305FP
PARP1ADPRT, PPOLBindingOlaparib, AZD5305, AZD9574SPR
PARP1ADPRT, PPOLTrappingOlaparib, AZD5305HTRF
PARP2ADPRT2, ADPRTL2ActivityOlaparib, AZD5305Luminescence
PARP2ADPRT2, ADPRTL2BindingOlaparib, AZD5305FP
PARP2ADPRT2, ADPRTL2BindingOlaparib, AZD5305, AZD9574SPR
PARP2ADPRT2, ADPRTL2TrappingOlaparib, AZD5305HTRF
PARP3ADPRT3, ADPRTL3ActivityOlaparib, AZD5305Luminescence
PARP3ADPRT3, ADPRTL3BindingOlaparib, AZD5305FP
PARP5aTNKS, PARPL, TIN1, TINF1, TNKS1ActivityXAV 939, Olaparib, AZD5305Luminescence
PARP5aTNKS, PARPL, TIN1, TINF1, TNKS1BindingOlaparib, AZD5305FP
PARP5bTNKS2, TANK2, TNKLActivityXAV 939, Olaparib, AZD5305Luminescence
PARP6PARP6-FLActivityOlaparib, AZD5305Luminescence
PARP6PARP6-FLBindingOlaparib, AZD5305FP
PARP7TIPARPActivityRBN-2397, Olaparib, AZD5305Luminescence
PARP10ADPRT, PARP-10ActivityOlaparib, AZD5305Luminescence
PARP11C12orf6ActivityTalazoparib, Olaparib, AZD5305Luminescence
PARP12ZC3HDC1ActivityOlaparib, AZD5305, RBN-2397Luminescence
PARP14BAL2, KIAA1268ActivityRBN-3143, Rucaparib, AZD5305Luminescence
PARP15BAL3ActivityOlaparib, AZD5305Luminescence
Cancer Cell Panel Screening for PARP

For PARP targets, we have launched specialized cell panels for PARP inhibitor screening.

01  30 or 50 cell lines targeting PARP1/2.
02  Validation of monotherapy and combination-therapy efficacy using engineered and drug-resistant cells.
03  Mutation information for PARP1/2-related genes, including BRCA status.
04  Assay duration: approximately 7 days.
05  Turnaround time: 2–3 weeks.

Contact Us

We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.

We are a CRO service organization, not a hospital




Get a quote

Go top